Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

Acta Oncol. 2017 Jan;56(1):101-103. doi: 10.1080/0284186X.2016.1260773. Epub 2016 Dec 2.

Authors

M K van der Kooij¹, A Joosse¹, F M Speetjens¹, G A P Hospers², C Bisschop², J W B de Groot³, R Koornstra⁴, C U Blank⁵, E Kapiteijn¹

Affiliations

¹ a Department of Clinical Oncology , Leiden University Medical Center , Leiden , The Netherlands.
² b Department of Medical Oncology , University Medical Center Groningen , Groningen , The Netherlands.
³ c Department of Medical Oncology , Isala , Zwolle , The Netherlands.
⁴ d Department of Medical Oncology , Radboud University Medical Center , Nijmegen , The Netherlands.
⁵ e Department of Medical Oncology , Netherlands Cancer Institute (NKI-AVL) , Amsterdam , The Netherlands.

PMID: 27911126
DOI: 10.1080/0284186X.2016.1260773

No abstract available

MeSH terms

Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / therapeutic use*
Female
Follow-Up Studies
Humans
Lymphatic Metastasis
Male
Melanoma / drug therapy*
Melanoma / epidemiology
Melanoma / secondary
Middle Aged
Neoplasm Staging
Netherlands / epidemiology
Nivolumab
Prognosis
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology*
Survival Rate
Uveal Neoplasms / drug therapy*
Uveal Neoplasms / epidemiology
Uveal Neoplasms / secondary

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab
pembrolizumab

Supplementary concepts

Uveal melanoma